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SUMMARY. Paeonol, a phenolic component from the root bark of Paeonia moutan, has been identified to
possess antitumor effects on mice bearing EMT6 breast cancer in our previous studies. However, the un-
derlying mechanisms remain unknown. In the present study the molecular mechanisms of paeonol were
further investigated in EMT6 mice model. The results showed that treatment of mice with 175 and 350
mg/kg/day of paeonol significantly inhibited the growth of the EMT6 tumor in mice, and induced tumor
cell apoptosis which were demonstrated by light microscopy after hematoxylin and eosin staining and
apoptosis analysis by flow cytometry. In addition, compared with the control group, paeonol increased the
number of tumor cells in G0/G1 phase but decreased the number of cells in S and G2/M phase. Paeonol
treatment (350 mg/kg body weight) also resulted in a decrease of Bcl-2 and an increase in Bax and cas-
pase-3 expressions, which were demonstrated by immunohistochemical and western blot analysis. These
results indicate that the antitumor effects of paeonol might be associated with arresting tumor cells in the
G0/G1 phase, inducing cell apoptosis and regulation of the expression of Bcl-2, Bax and activation of cas-
pase-3.
RESUMEN. Peonol, un componente fenólico de la corteza de la raíz de Paeonia moutan Sims., ha demostrado
poseer efectos antitumorales en ratones portadores de cáncer de mama EMT6 en nuestros estudios anteriores. Sin
embargo, los mecanismos subyacentes siguen siendo desconocidos. En el presente estudio los mecanismos mole-
culares de peonol se investigaron en ratones modelo EMT6. Los resultados mostraron que el tratamiento de rato-
nes con 175 y 350 mg/kg/día de paeonol inhibió significativamente el crecimiento del tumor EMT6 en ratones y
se indujeron la apoptosis de células tumorales, lo que se demostró por microscopía después de tinción con hema-
toxilina y eosina y el análisis de la apoptosis por citometría de flujo. Además, en comparación con el grupo de
control, peonol aumentó el número de células tumorales en la fase G0/G1 pero disminuyó el número de células
en fase S y G2/M. El tratamiento con paeonol (350 mg/kg de peso corporal) también dio lugar a una disminución
de la expresión de Bcl-2 y un aumento de Bax y caspasa-3, que se demostraron por análisis de western blot e in-
munocitoquímica. Estos resultados indican que los efectos antitumorales de peonol podrían estar asociados con
la detención de las células tumorales en la fase G0/G1, la inducción de la apoptosis y la regulación de la expre-
sión de Bcl-2, Bax y la activación de la caspasa-3.
INTRODUCTION
Paeonol is a micromolecular phenolic com-
pound and it is the main active component that
has been isolated from the root bark of the
plant Paeonia moutan, which grows in north-
west and southwest area of China. Paeonol is
traditionally used as a Chinese herbal medicine
that has been widely used in sedation, hypnosis,
antipyresis, analgesia, antioxidation, antiinflam-
mation, anti-bacteria and to activate the blood
flow and remove blood stasis 1-4. It has been re-
ported that paeonal has the antitumor effect and
inhibits the proliferation of different tumor cell
lines which include the human erythromyeloid
cell line K562, the breast cancer gene cell lines
T6-17, the human hepatoma cell line Bel-7404,
the cervical cancer cell line Hela and the human
colorectal cancer cell line HT-29. Furthermore,
paeonol can enhance the anti-tumor effect
against oesophageal cancer in vitro when it
combined with cisplatin 5-8. 
Previously, we reported the anti-tumor ef-
102
SONG H., WANG J., LI L., WANG M., DONG H., LUO W. & ZHOU S.
fects of paeonol on mice bearing EMT6 breast
carcinoma, and indicated that its mechanisms
might be associated with inhibition of tumor
cells in G0/G1 phase and reduction of the ex-
pression of mutant p53, Bcl-2 and C-erbB-2 pro-
tein 9, but there was no detailed report on the
mechanism of paeonol against breast cancer
through inducing apoptosis.
Therefore, the study was further to explore
the possible mechanisms responsible for the an-
ti-tumor activity of paeonol using EMT6 bearing
mice model. The purpose was to find the thera-
peutic potential of paeonol for breast cancer
and to provide a scientific explanation. 
MATERIALS AND METHODS
Chemicals and instruments
Paeonol was obtained from Beijing Pharma-
ceutical University (Beijing, China). Cyclophos
phamide (CTX) was purchased from HengRui
pharmacy Inc. (Jiangsu province, China). Prodi-
um Iodine RNase was obtained from sigma
chemical co. (St Louis, MO, USA). Mouse anti-
Bcl-2, anti-Bax and anti-caspase 3 monoclonal
antibodies and Streptavidinbiotin Peroxidase im-
munohistochemical reagent kits were obtained
from Santa Cruz Bio Inc. (Santa Cruz, CA, USA).
Horseradish peroxidase-labeled rabbit antigoat
IgG antibody and actin polyclonal antibody
were purchased from Biosynthesis Bio. The en-
hanced chemiluminescence kit was purchased
from Amersham Pharmacia Biotech. The EMT6
cell line was obtained from Cancer Institute of
Chinese Academy of Medical Sciences. Flow cy-
tometry was conducted using an EPICS XL mod-
el of American Beckman Coulter. All other
chemicals used were of analytical reagent grade.
Animals
Fifty female Kunming mice (6 weeks-old)
were purchased from the Laboratory Animal
Center of the Academy of Military Medical Sci-
ences. All animal experiment was conducted in
accordance with the NIH Guide for the care and
Use of Laboratory Animals (NIH Publication
No.80-23; revised 1978 and the number ap-
proved by Administrated-Committee of Labora-
tory Animals was 062310). The mice were ran-
domLy divided into five groups. Each group had
ten animals. One group was used for the prepa-
ration of EMT6 tumor cell. The other four
groups were used for different treatments. Ani-
mals were housed in plastic cages with free ac-
cess to food and water and maintained on a
regulated environment (20 ± 2 °C).
Prepared EMT6 tumor cells 
The EMT6 breast cancer cell line (107 cell/
mL) was injected into the right fore limb in one
group of mice (0.2mL/mouse). We removed sol-
id tumor when tumor size grew to 1cm to make
cell suspension and diluted to concentration of
5 × 106 cell/mL under aseptic condition in nor-
mal saline. 
Animal model and treatment with drugs
Four groups of mice were all injected with
0.2 mL/mouse of 5 × 106/mL EMT6 breast can-
cer cells in the skin under the right fore limb.
Then 24 h after tumor inoculation, one group
was administered with vehicle alone (distilled
water, p.o.) as the control group. One group
was given cyclophosphamide (CTX, 25 mg/kg
body weight, i.p.), a standard antitumor refer-
ence drug, which was designated as the positive
control group (CTX group). The other two
groups were administrated paeonol, low dosage
(175 mg/kg body weight, p.o.) and high dosage
(350 mg/kg body weight, p.o.), separately. After
15 days, all mice were weighed and killed, and
then tumor was removed and weighed. Accord-
ing to the mean weight of tumor, the rate of tu-
mor inhibition was calculated as follows: The
rate of inhibition (%) = (mean tumor weight of
control group - mean tumor weight of treated
group) /mean tumor weight of control group ×
100.
Morphology analysis of tumor tissues
Tumor specimens which collected from the
control group, CTX group and paeonol group
(350 mg/kg) were fixed in 10% (v/v) neutral for-
malin solution, dehydrated through a graded
ethanol series and embedded in paraffin. Tissue
sections (4 µm) were stained with hematoxyli
and eosin and then examined under the light
microscope.
Cell cycle and apoptosis assay by flow
cytometry
The tumors which were collected from the
control group, CTX group and paeonol group
(350 mg/kg) were minced, single cell suspen-
sion was prepared with 200 mesh filtering, cen-
trifuged at 956 g for 5 min, washed three times,
adjusted cell concentration to 106 cell/mL, fixed
with 70% ethanol for 30 min at 4 °C, and DNA
content and cell cycle were analyzed by flow
cytometry after treatment with RNase and Pro-
pidium Iodide staining for 30 min. The propor-
tion of cells in each cell cycle and apoptosis
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number were calculated. The data were ana-
lyzed with CellQuest software.
Immunohistochemical analysis for Bc1-2,
Bax, and caspase-3 in tumor tissues
Tumor specimens which collected from the
control group, CTX group and paeonol group
(350 mg/kg) were fixed in 10% (v/v) neutral for-
malin solution and embedded in paraffin. Tu-
mor sections were prepared and used to exam-
ine the expression of Bc1-2, Bax, and caspase-3
proteins. The tumor sections were stained by
the standard immunohistochemical streptavidin
peroxidase method which was described in the
program of streptavidin peroxidasereagents kit.
The cells which stained brown suggested posi-
tive cells while blue cells indicated negative
cells under a microscope. Image was acquired
by using Leica Application suite software (Leica
Microsystems Ltd. Germany), and the average
number of positive cells was counted by using
Leica Qwin software (Leica Microsystems Ltd.
Germany) in five randomLy selected optical
fields (200 tumor cells/per field). The average
positive rate was calculated as follows: Positive
rate (%) = number of positive cells/total number
of cells × 100.
Western blot analysis for Bc1-2, Bax, and
caspase-3
Tumor tissues from the four groups were
minced and lysed in 500 µL cell lysis buffer for
30 min, and centrifuged at 12,000 g for 15 min
at 4 °C. The supernatant was collected and pro-
tein concentrations were determined according
to the Bradford method. after samples were
boiled for 5 min, they were subjected to 10%
sodium dodecylsulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) and the resolved pro-
teins were electrophoretically transferred to
polyvinylidene difluoride membranes by a semi-
dry transfer method. The membranes were
blocked with 5% non-fat dried milk in Tris-
Body weight (g)
Group n
Beginning End
Control 10 Vehicle 19.48 ± 1.62 23.69 ± 2.31 2.49 ± 0.36
CTX 10 25 20.12 ± 1.53 18.76 ± 1.77 1.01 ± 0.27* 59.45
Paeonol
10 175 19.68 ± 1.72 22.93 ± 1.49 1.38 ± 0.53* 44.58
10 350 20.13 ± 1.61 23.64 ± 2.16 1.15 ± 0.24* 53.82
Table 1. The inhibitory effect of paeonol on EMT6 solid tumor (x ± s). *p < 0.05 as compared with control
group, values are mean ± SD.
Treatment
(mg/kg)
Mean weight
of tumor (g)
Inhibition
Rate (%)
buffered saline containing 0.1% Tween 20 (TB-
ST) for 1 h at room temperature, washed three
times with TBST, and incubated with TBST con-
taining 5% of dried skim milk and primary anti-
body (Bcl-2, Bax or caspase 3) for 2 h at room
temperature. After washing three times with TB-
ST, the membranes were incubated with
horseradish peroxidase-conjugated secondary
antibody for 1 h at room temperature. Proteins
were visualized by using an enhanced chemilu-
minescence kit and exposed to X-ray film. At
the same time, β-actin was used as an internal
control for all Western blots. The intensity of
protein bands was quantified by using LabWork
3.0 UVP software.
Statistical analysis 
All values are expressed as mean ± S.D.
One-way analysis of variance and Duncan’s
multiple range tests were used for determining
differences among the groups, and p < 0.05 was
regarded as statistically significant.
RESULTS
Effect of paeonol on solid tumor growth
After tumor-bearing mice were treated with
two dosages of paeonol 175 or 350 mg/kg body
weight and CTX for 15 days, there was no sig-
nificant influence on the body weight of mice in
both the paeonol group and CTX group. How-
ever, comparing with the control group,
paeonol administration of 175 and 350 mg/L sig-
nificantly decreased the tumor weight in a dose-
dependent manner and the tumor inhibition
rates reach 44.58 and 53.82%, respectively. CTX,
which is the standard chemotherapeutic, pro-
duced an inhibition rate of 59.45% (Table 1).
Morphological changes of cell apoptosis 
Tumor cells in the control group were ar-
ranged closely in different sizes and shapes, a
little cytoblastema and bigger nucleus with a
thickly staining and obvious heteromorphism,
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and hyperplasia as well. As shown in Fig. 1, the
number of tumor cells in the paeonol treatment
groups decreased markedly, and tumor cell
chromatin accumulated at the side of the nucleic
membranes. The nucleic shape was irregular
and the surface of the nucleic membrane was
rough. The nucleus was broken but was encap-
sulated by intact membrane, containing intact
organelles and apoptotic bodies. Light mi-
croscopy comparison with the control group re-
vealed more apoptotic cells in the paeonol
group. 
Effect of paeonol on tumor cell cycle
After administration of CTX and paeonol
(paeonol 350 mg/kg), the percentage of tumor
Figure 1. Morphology of EMT6 breast cacerrcinoma cell (H.E. ×400). A: control group; B: CTX group; C:
paeonol group.
Figure 2. The effect of paeonol on cell cycle and apotosis. A: control group; B: CTX group; C: paeonol group.
Figure 3. Effect of paeonol on the expression of Bcl-2 protein in EMT6 tumor tissues (S-P ×400). A: control
group; B: CTX group; C: paeonol group.
cells in G0/G1 phase was increased significantly
from 39.6% in the control group to 50.7% in CTX
group and 59.2% in paeonol group. Correspond-
ingly, the percentage of group sub-G1 cells as
apoptotic cells was also significantly increased
from 4.7% in the control group to 7.2% in CTX
group and 22.6% in paeonol group. However,
compared to the control group, CTX and
paeonol reduced the proportion of tumor cells
in the S and G2/M phases. These data indicated
that paeonol arrested the cell cycle in G0/G1
phase and induced tumor cell apoptosis (Fig. 2).
Effects of paeonol on the expression of Bc1-
2, Bax and caspase-3 proteins
The expression of Bc1-2, Bax and caspase 3
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proteins were examined with the Streptavidin
Peroxidase method and Western blotting. Com-
paring with the control group, administered
with paeonol (350 mg/kg) reduced the expres-
sion of Bc1-2 while increased the expression of
Bax and caspase 3 proteins. The positive rate of
Bcl-2 was 71.24% in the control group, adminis-
tered with CTX and paeonol, the positive num-
ber of Bcl-2 decreased to 33.51% in CTX group
and 24.37% in paeonol group (Table 2, Fig.3).
The positive rate of Bax was 28.65% in the con-
trol group, after administration with CTX and
paeonol, the positive number of Bcl-2 increased
significantly to 47.24% and 64.72%, respectively.
(Table 2, Fig. 4). Similar to Bax, the positive
percentage of caspase-3 was 33.62% in the con-
trol group while the treatment of CTX and
paeonol significantly increased the number of
caspase-3 positive cells to 57.49% in CTX group
and 81.26% in paeonol group (Table 2, Fig. 5).
The expression of Bcl-2, Bax and caspase 3
Figure 4. Effect of paeonol on the expression of Bax protein in EMT6 tumor tissues (S-P ×400). A: control
group; B: CTX group; C: paeonol group.
Groups Treatment mg/kg Bcl-2 Bax Caspase-3
Control Vehicle 71.24 ± 8.84 28.65 ± 6.25 33.62 ± 7.34
CTX 25 33.51 ± 7.48* 47.24 ± 7.61* 57.49 ± 8.27*
Paeonol 350 24.37 ± 5.42* 64.72 ± 9.44* 81.26 ± 6.73*
Table 2. The effect of paeonol on the expression of Bcl-2, Bax and caspase-3 (x ± s,%). *p<0.05 as compared
with control group, values are mean± SD.
Figure 5. Effect of paeonol on the expression of Caspase-3 in EMT6 tumor tissues (S-P ×400). A: control group;
B: CTX group; C: paeonol group.
proteins were further detected using western
blotting. As shown in Fig. 6, the result was simi-
lar to the immunohistochemical assay, which
showed that the expression of Bcl-2 was re-
duced while the expression of Bax and caspase
3 was increased, and the down-regulation of
Bcl-2 and up-regulation of Bax led to a decrease
in the ratio of Bcl-2/Bax (Fig. 6A, B, C, D).
DISCUSSION
Breast cancer is the second most common
cancer in females in the world and there are
about more than 1.5 million cases and 570 thou-
sand of patients die of breast cancer per year.
Recently, the rate of incidence is the tendency
of increasing 10. The current therapeutic ap-
proaches include surgery, chemotherapy, and
radiotherapy which can give patients a higher
survival rate. However, the prognosis of these
patients is poor because it often recurs in sever-
al years 11-13. Therefore, to explore new com-
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pounds for potential use as effective therapeutic
agents for breast cancer is an important under-
taking. 
Paeonol is identified to have various physio-
logical activities. It had been also reported that
paeonol had the anti-tumor effect. However, the
underlying mechanism of the anti-tumor proper-
ty of paeonol has not yet been fully elucidated.
Therefore, we need further explored the possi-
ble mechanism of paeonol against breast cancer.
In the present study, paeonol exhibits antitu-
mor biochemical activity on mice with EMT6
breast carcinoma in a dose-dependent manner.
After administrated with paeonol, Tumor growth
was inhibited and tumor cells appeared typical
morphological alterations of the apoptosis, in-
cluding reduction in cell volume, chromation
condensation, deformed and fragment nuclei,
and so on. Furthermore, after paeonol treat-
ment, apoptotic peak (Sub-G1 phase), which re-
sulted from the internucleosomal degradation of
DNA appeared before G1 phase, These results
Figure 6. Western blot analysis for Bcl-2, Bax, and caspase-3 in tumor tissue. A: Bcl-2, Bax and caspase-3 ex-
pression by western blot method. β-actin was used as a control; B: The intensity of Bcl-2 and Bax bands was
quantified and was shown as relative expression level after normalized by β-actin. *P < 0.05, vs. control group.
C: the ratio of Bcl-2/Bax was showed. *P < 0.05 vs. control group. D: The intensity of caspase 3 was quantified
and was shown as relative expression level after normalized by β-actin. P < 0.05, vs. control group.
indicated that inhibition effects of paeonol on
breast cancer mice was through inducing tumor
cell apoptosis.
Apoptosis is one of the types of programmed
cell death, which enables organisms to eliminate
malignant cells that threaten survival. Many anti-
cancer drugs may induce tumor cell apoptosis
and the induction of apoptosis in tumor cells is
generally regarded as a valid measure for anti-
cancer therapy. The mechanisms of apoptosis
induced by drugs are complex because of the
differences in cell types and drugs 14. However,
mitochondrial and cell-surface death receptor
mediated apoptosis are the two principal path-
ways. The mitochondrial pathway is thought to
play a major role in response to cancer treat-
ments and is mediated by the Bcl-2 family pro-
teins, which are always over-expressed in many
tumor cells 15-17. Bcl-2 family proteins are act as
repressors of apoptosis by blocking the release
of cytochrome-c, whereas pro-apoptotic mem-
bers (Bax) act as promoters. These effects are
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more dependent on the balance between Bcl-2
and Bax than on Bcl-2 quantity alone 18-19. 
Many researches have shown that paeonol
induced apoptosis in human gastric cancer cell
lines and esophageal cancer cell lines by down-
regulating the expression of Bcl-2 and regulat-
ing the activity of caspase-3; induced cell death
involving apoptosis by regulation of apoptosis
related-gene Bcl-2 and Bax expression in mouse
HepA-hepatoma and human colon cancer cell
lines 5,20-22. These suggested that one of apoptot-
ic mechanisms induced by paeonol was to trig-
ger the mitochondrial-dependent pathway and
associated with caspase-3 activation. So, in this
study, the expressions of Bcl-2 family and cas-
pase-3 were examined. The results indicated
that paeonol decreased the expression of Bcl-2
and increased the expression of Bax and fol-
lowed by the activation of caspase-3. The up-
regulation of Bax expression and the reduction
of Bcl-2 expression in the treated groups led to
a decrease in the ratio of Bcl-2/Bax, which
might be responsible for the drug-induced
apoptotic processes. Caspase-3 is an executioner
caspase of apoptosis pathway 23-24. In the cur-
rent study, after administration with paeonol
there was a considerable increase in caspase-3
protein levels, which indicated that paeonol also
promoted caspase-3 protein expression. These
results suggested that the apoptosis-induction
effect of paeonol might occur through the mito-
chondrial-dependent pathway, finally leads to
the activation of the caspase-3, and eventually
lead to apoptosis.
CONCLUSION
The results of the study suggest that paeonol
result in the growth inhibition of tumor cells by
inducing apoptosis, and its mechanisms likely
occur through the triggering of the mitochondri-
al-dependent pathway and caspase-3 activation.
Paeonol, as traditional natural plant compounds,
may be a novel chemotherapy against breast
cancer. 
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